Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 10, 2016

View Archived Issues

AstraZeneca reflects on highlights of fourth quarter 2015

City of Hope develops technology to create cell-permeable antibodies

OncoMed gives update on ALPINE and PINNACLE studies of tarextumab

PharmaMar's phase III lurbinectedin study to continue

Aurinia Pharmaceuticals completes preliminary analysis of AURION study

Innov17 patents retinoid-related orphan receptor ligands

Cisen Pharmaceutical and Medshine Discovery reveal compounds to treat tuberculosis

FDA places full clinical hold on pacritinib

New animal model created for the investigation of glanders

PDS Biotechnology and NCI to codevelop novel cancer immunotherapies

Adaptimmune's NY-ESO T-cell therapy earns FDA breakthrough therapy designation

Sanofi presents milestones of fourth quarter 2015

Study of amifampridine phosphate in MuSK-antibody positive myasthenia gravis begins

Novel fibrinogen mutations are associated with congenital hypofibrinogenemia

VBI and GSK enter vaccine research collaboration

Phase I data support progression of Immune Design's immuno-oncology candidates

Cellceutix plans SPA request for phase III study of brilacidin in ABSSSI

Target for interfering with MYC oncogene activity identified

Merck & Co. files BLA for house dust mite SLIT tablet

Scientists identify unusual mutations in moderate hemophilia B patients

FDA recommends approval of Celltrion's infliximab biosimilar, Epirus advances own biosimilar

BioCryst reports phase II/III results for liquid capsule formulation of avoralstat

Nymox announces results from phase II prostate cancer study

EMA creates Zika virus task force, HemispheRx announces its approach

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Psychedelic space expanding on Trump’s EO
BioWorld
Timothy Leary is dead, but he could be on the outside looking in with a smile on his face as U.S. President Donald Trump’s latest executive order (EO) fuels a...
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...